Study of Different Doses of Irinotecan and Cisplatin for First-line Extensive-stage Small-cell Lung Cancer Treatment

Phase 2

• Conditions: Small Cell Lung Cancer
• Interventions: Drug: irinotecan

• Registration Number: NCT02171325
• Lead Sponsor: Guangdong Association of Clinical Trials

Brief Summary

The purpose of this study is to identify the appropriate dose of irinotecan by dose escalation(dose climbing) test. The study would provide rationale for regimen decision in a future phase III clinical trial, in which irinotecan combined with cisplatin(IP) will be selected as therapeutic drugs.

Detailed Description

To determine the Maximum Tolerated Dose (MTD) and Limiting Toxicity (DLTs) of irinotecan in patients with extensive stage small cell lung cancer treated with irinotecan plus cisplatin

Study Timeline

• Study Start: 2014-06
• Study First Submitted: 2014-06-16
• Study First Submitted QC: 2014-06-20
• Study First Posted: 2014-06-24
• Status Verified: 2021-02
• Last Update Submitted: 2021-02-02
• Last Update Posted: 2021-02-03
• Primary Completion: 2021-06
• Study Completion: 2021-06

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 54

Inclusion Criteria

1. Age 18 to 65 years, male and female

2. Histologically or cytologically confirmed extensive stage .small cell lung cancer(SCLC )（except metastases only as pleural effusion）

3. No prior chemotherapy

4. Metastatic lesion had been treated more than 14 days by palliative radiation therapy or surgery

5. With measurable tumor lesions (Non-irradiated parts),(RECIST 1.1: Without radiotherapy ,the longest diameter is more than 10mm by CT or MRI ,except that lymph nodes need short diameter need more then 15mm, and the lesions can be accurately evaluated repeatedly measurable)

6. Eastern Cooperative Oncology Group(ECOG) Performance Status 0-1

7. Expected survival ≥ 3months

8. Marrow,kidney, liver,heart and lung are well -functioning,and absolute count of

   • absolute neutrophil coun(ANC) ≥ 2.0 × 109 / L
   • blood platelet(PLT) ≥ 100 × 109 / L
   • Hb≥ 90g / L
   • conjugative bilirubin(CB)≤ upper limit of normal(ULN) × 1.5
   • Aspartate transaminase(AST )(glutamic oxalacetic transaminase,GOT): ≤ upper limit of normal(ULN )× 2.5
   • Alanine aminotransferase(ALT)(Glutamate Pyruvate Transaminase,GPT): ≤ ULN × 2.5
   • Serum creatinine: ≤ ULN or calculated creatinine clearance≥ 60 ml / min
   • (PT INR) ≤ ULN × 1.5
   • ECG: no abnormalities in need of treatment

9. No pregnancy or no pregnancy demand at the end of the study within six months

10. Must provide written informed consent.

Exclusion Criteria

1. Patient have platinum compounds allergy history
2. Patient with active ulcer disease or chronic enteritis patients
3. Primary lesion(s) has (have) been treated by Surgery or radiation
4. Patient had received Immune drugs treatment for anti-lung cancer indications or anti-cancer Chinese traditional medicine treatment within two weeks
5. Patients with interstitial pneumonia or pulmonary fibrosis
6. Brain metastasis requiring treatment
7. Patient with bronchus or bronchial stenosis or blockage and superior vena cava syndrome caused by serious invasion
8. Patients with severe infections, severe abnormal secretion of (Anti Diuretic Hormone,ADH) syndrome, poorly controlled diabetes, severe complications requiring treatment vena cava syndrome
9. Severe cardiovascular disease: hypertension that medical treatment can not be controlled , unstable angina, myocardial infarction within the last June a history of congestive heart failure> 3 (NYHA) and severe arrhythmia

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
irinotecan	irinotecan	irinotecan； 60 mg/m2、65mg/m2、70mg/m2、75mg/m2、80mg/m2、85mg/m2、90mg/m2、95mg/m2、100mg/m2

Primary Outcome Measures

Name	Time	Method
Limiting Toxicity (DLT )in the irinotecan	up to 18 weeks

Secondary Outcome Measures

Name	Time	Method
Maximum Tolerated Dose(MTD)in the irinotecan	up to 18weeks

Trial Locations

Locations (1)

Jilin cancer hospital; 🇨🇳 Changchun, Jilin, China